Tamer Acat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tamer Acat has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Karakurt
Pazaryeri Public Hospital, Bilecik, Türkiye
2 shared publications - Cansu Arslantürk Güneysu
Department of Internal Medicine Rheumatology, Faculty of Medicine, Sakarya University, Sakarya, Türkiye
2 shared publications - Damla Karataş
Department of Internal Medicine Rheumatology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye
2 shared publications - Emel Gönüllü
Department of Rheumatology, Sakarya Training and Research Hospital, Sakarya, Türkiye
2 shared publications - Gamze Dilek
Rheumatology Clinic, Bolu Abant Izzet Baysal University Izzet Baysal Training and Research Hospital, Bolu 14000, Türkiye
2 shared publications - Gokhan Yavuzbilge
Department of Internal Medicine, Division of Rheumatology, Medical Faculty, Ondokuz Mayıs University, Samsun, Turkey
2 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 6 (2) , 144-148
Do age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?
Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.
- 10 April 2026
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 6 (2) , 144-148
Open AccessDo age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?
Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.
- Open Access
- 10 April 2026
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 6 (2) , 144-148
Do age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?
Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.
- 10 April 2026
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 6 (2) , 144-148
Open AccessDo age at disease diagnosis and age at symptom onset affect cognitive functions in Sjögren's syndrome?
Objectives: In this study, we aimed to investigate the relationship between the age of onset of disease symptoms, the age at diagnosis, and cognitive function in patients with primary Sjögren's syndrome (pSS). Methods: Sixty-two patients diagnosed with pSS who presented to the Sakarya Training and Research Hospital Internal Medicine Rheumatology outpatient clinic between November 2021 and November 2022 were included in the study. Parameters such as age at diagnosis, age at symptom onset, fibromyalgia status, Beck Depression Inventory (BDI) score, Beck Anxiety Inventory (BAI) score, insomnia, fatigue, learning disability, and number of comorbidities were recorded. The Montreal Cognitive Assessment (MoCA) score was used to evaluate cognitive function. The scale ranges from 0 to 30, with a threshold value set at 21. Scores of 21 and above were considered normal. Independent samples t-tests, Mann-Whitney U tests, and chi-square tests were used for data comparison. Results: Patients with MoCA values less than 21 were significantly older. In the study, the age at symptom onset for patients with a MoCA score<21 was significantly higher than for those with a MoCA score ≥ 21 (p<0.05). Similarly, the age at diagnosis for patients with MoC<A values<21 was significantly higher than for those with MoCA values ≥ 21 (p<0.05). The impaired group (MoCA<21) comprised 20 individuals, representing 32.2%±3% of the cohort, while the non-impaired group consisted of 42 individuals, accounting for 67.7%±4% of the patients (p<0.001). A negative correlation was detected between age at the onset of symptoms (r=-0.376, p=0.003), disease diagnosis age (r=-0.297, p=0.019), and the MoCA value. Conclusion: In our study, a negative correlation was found between age at the onset of symptoms, age at diagnosis, and MoCA values. Early diagnosis and treatment of SS can minimize cognitive dysfunction that may develop during the disease process. Maintaining high cognitive function will positively affect the quality of life.